SXI vs ERAS Comparison

Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.